Loading
GoodRx Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 04 Dec 2023.
GoodRx Holdings, Inc.: what insiders have been doing
Every trade that managers of GoodRx Holdings, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Santa Monica, United States. It was founded in 2011. From 18 October 2025 to 18 October 2026, the disclosure feed for GoodRx Holdings, Inc. logged 101 filings by 13 insiders.
Only sales appear on the open market, 14 sales in all totalling €8.3M, filed by 1 insider. At €1.3M, the sale published on 26 August 2026 by Francisco Partners IV, L.P. is the largest of the period (0.13% of market cap).
For context, the typical company on the same exchange (median of 5,813 companies) published 19 filings over the same period, against 101 filings here. Over the whole record (from 2021), the tally stands at 6 purchases and 35 sales. The 10-K for the year ended 31 December 2025 shows 796.9 m USD of revenue and 30.4 m USD of net income.
Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
311
Thresholds
n/a
Buy Volume
€991,396
6 ops. · all time
Sell Volume
€31M
35 ops. · all time
Who traded when
BuySaleFrancisco Partners IV, L.P.14 sales
Since the insiders bought
- -16.7%Entry US$6.09 · Close at T+365 US$5.07
- -85.6%Entry US$44.61 · Close at T+365 US$6.42
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate GoodRx Holdings, Inc. Hold (neutral), based on 12 analysts. Average price target: US$3.95.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,303 of 24,148 companies
57.3
score / 100
Value62
Quality53
FCF yld7.9%
Earn yld2.5%
EV/EBITDA9.4x
ROE2.5%
Gross mgn93%
Net mgn3.8%
Debt/EBITDA2.9x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.51
Analyst consensus
12 analystsHold
US$2.65Target US$3.95(+13%)US$5.00
Income statement
RevenueUS$796.9M
Gross profitUS$739.3M93% margin
EBITDAUS$184.4M23% margin
Net incomeUS$30.4M2.1% margin
Valuation
PER (trailing)70.1x
PER (forward)10.0x
P/Book1.8x
Beta1.69
Balance sheet & cash
Market capUS$1.2B
Total debtUS$542.8M
Free Cash FlowUS$93.9M
Debt / Equity83%
Profitability & ownership
ROE2.5%
ROA3.0%
% insiders12.7%
% institutions55.6%
Last declaration on 15 October 2026
Declarations311 total
32,490 sharesClass A Common StockSEC:0001809519-26-000177:0
5,793 sharesClass A Common StockSEC:0001809519-26-000175:0
51,177 sharesClass A Common StockSEC:0001809519-26-000173:2
110,963 sharesClass A Common StockSEC:0001809519-26-000173:4
48,203 shares@ US$3.380.014% mcap16.0% of flowClass A Common StockSEC:0001809519-26-000173:5
14,247 shares@ US$3.380.0041% mcap36.9% of flowClass A Common StockSEC:0001809519-26-000177:1
2,948 shares@ US$3.380.0008% mcap20.8% of flowClass A Common StockSEC:0001809519-26-000175:1
115,149 sharesClass A Common StockSEC:0001809519-26-000173:0
50,021 shares@ US$3.380.014% mcap16.6% of flowClass A Common StockSEC:0001809519-26-000173:1
22,232 shares@ US$3.380.0064% mcap7.4% of flowClass A Common StockSEC:0001809519-26-000173:3
2,101 sharesClass A Common StockSEC:0001809519-26-000171:0
1,069 shares@ US$3.560.0003% mcap9.8% of flowClass A Common StockSEC:0001809519-26-000171:1
2,335 sharesClass A Common StockSEC:0001809519-26-000169:0
1,024 shares@ US$3.560.0003% mcap4.3% of flowClass A Common StockSEC:0001809519-26-000169:1
752 sharesClass A Common StockSEC:0001809519-26-000169:2
330 shares@ US$3.560.0001% mcap1.4% of flowClass A Common StockSEC:0001809519-26-000169:3
433,088 shares@ US$3.500.13% mcap15.6% of flowClass A Common StockSEC:0001193125-26-369287:7
72,309 shares@ US$3.4620.021% mcap2.6% of flowClass A Common StockSEC:0001193125-26-369287:0
71,285 shares@ US$3.4620.021% mcap2.5% of flowClass A Common StockSEC:0001193125-26-369287:1
64,090 shares@ US$3.44490.019% mcap2.3% of flowClass A Common StockSEC:0001193125-26-369287:2
63,183 shares@ US$3.44490.019% mcap2.2% of flowClass A Common StockSEC:0001193125-26-369287:3
213,401 shares@ US$3.51250.064% mcap7.7% of flowClass A Common StockSEC:0001193125-26-369287:4
210,378 shares@ US$3.51250.063% mcap7.6% of flowClass A Common StockSEC:0001193125-26-369287:5
439,310 shares@ US$3.500.13% mcap15.9% of flowClass A Common StockSEC:0001193125-26-369287:6
136,379 shares@ US$3.49680.041% mcap4.9% of flowClass A Common StockSEC:0001193125-26-361608:9
25 of 311 declarations
About GoodRx Holdings, Inc.
GoodRx Holdings, Inc. (ticker: GDRX) is a U.S.-listed company traded on the Nasdaq market in the United States, positioned at the intersection of digital health, prescription affordability, and consumer healthcare services. Founded in 2011 and headquartered in Santa Monica, California, GoodRx was built around a straightforward but highly relevant mission: helping consumers compare prescription prices, access discounts, and understand their medication options more clearly. For French-speaking investors, the company stands out as a hybrid between a healthcare marketplace, a consumer platform, and a health-information business, with economics tied to prescription transparency and patient engagement.
At its core, GoodRx operates a medication savings platform accessed through its website and mobile apps. The company aggregates pricing data from thousands of pharmacies across the United States and offers coupons, discount cards, and comparison tools for both generic and brand-name medicines. Over time, GoodRx has expanded beyond its original prescription-savings model into broader digital health services, including telehealth-related offerings, consumer health content, and commercial solutions for pharmaceutical manufacturers. This broadening of the platform is important strategically because it helps diversify revenue sources and reduce reliance on any single line of business.
Read moreShow less
From a competitive standpoint, GoodRx benefits from strong brand recognition among U.S. consumers, particularly those looking for out-of-pocket savings on prescriptions. Its value proposition is supported by a large user base, nationwide pharmacy reach, and data capabilities focused on medication pricing and consumer behavior. The company competes in a fragmented but highly complex ecosystem involving pharmacies, pharmacy benefit managers, drug manufacturers, insurers, and digital health platforms. GoodRx’s relevance is reinforced by the fact that medication affordability remains a persistent issue in the United States.
Its key products and services include prescription coupons, pharmacy price-comparison tools, manufacturer solutions, telehealth and care-navigation offerings, and health content that supports user retention and monetization. In recent years, GoodRx has also placed more emphasis on higher-growth, strategically important initiatives such as GLP-1-related access programs and partnerships linked to weight management therapies. These initiatives illustrate the company’s effort to reposition itself from a pure savings platform toward a broader prescription and care-access ecosystem.
Recent highlights include new commercial offerings around GLP-1 medications such as Ozempic and Wegovy, as well as 2025 earnings updates showing disciplined cost control and a continued strategic shift in the business mix. The company has also continued share repurchases, which often matter to Nasdaq investors looking at capital allocation. Overall, GoodRx remains a notable U.S. digital healthcare player whose investment case is closely tied to prescription affordability trends, platform expansion, and the evolution of pharmaceutical pricing dynamics in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
